Intervention group (n = 24) | Control group (n = 23) | P-value | |||
---|---|---|---|---|---|
Age (years) | 75 | (67–81) | 73 | (68–78) | 0.64 |
Male sex, n (%) | 17 | (70.8%) | 15 | (65.2%) | 0.92 |
eGFR (mL/min/1.73 m2) | 36 | (19–45) | 34 | (22–50) | 0.72 |
CKD classification, n (%) | 0.27 | ||||
Stage 3 | 17 | (70.8%) | 13 | (56.5%) | |
Stage 4 | 2 | (8.3%) | 6 | (26.1%) | |
Stage 5 | 5 | (20.8%) | 4 | (17.4%) | |
Cause of renal failure, n (%) | 0.50 | ||||
Hypertension | 12 | (50.0%) | 10 | (43.5%) | |
Diabetes mellitus | 7 | (29.2%) | 11 | (47.8%) | |
Polycystic kidney disease | 2 | (8.3%) | 1 | (4.3%) | |
Other | 3 | (12.5%) | 1 | (4.3%) | |
MNA-SF scores | 12 | (11–14) | 13 | (11–14) | 0.26 |
Physical activity | |||||
IPAQ-SF scores (MET-min/week) | 953 | (223–2993) | 2319 | (693–4986) | 0.10 |
Body composition | |||||
Body weight (kg) | 61.0 | (48.2–68.1) | 67.3 | (54.8–73.2) | 0.06 |
BMI (kg/m2) | 23.5 | (20.8–25.2) | 24.2 | (23.0–27.4) | 0.11 |
Body fat (%) | 20.4 | (17.8–23.3) | 23.4 | (18.8–28.7) | 0.10 |
Fat mass (kg) | 12.3 | (9.9–15.0) | 15.7 | (10.3–20.5) | 0.08 |
Muscle mass (kg) | 44.5 | (35.5–52.0) | 45.8 | (39.4–50.9) | 0.59 |
Fat-free mass (kg) | 47.0 | (37.5–54.9) | 48.9 | (41.9–53.7) | 0.58 |
Extracellular water (kg) | 14.7 | (12.7–16.3) | 15.4 | (13.9–16.0) | 0.52 |
Intracellular water (kg) | 17.9 | (14.0–23.3) | 19.4 | (16.8–22.1) | 0.46 |
Skeletal muscle index (kg) | 7.5 | (6.3–8.5) | 7.8 | (6.5–8.7) | 0.55 |
Resistance at 50 kHz (Ω) | 564 | (504–622) | 549 | (502–594) | 0.55 |
Phase angle (°) | 5.5 | (4.7–6.0) | 5.6 | (5.0–5.9) | 0.65 |
Physical performance | |||||
Hand grip strength (kg) | 24.1 | (17.0–30.6) | 26.9 | (19.6–31.4) | 0.44 |
Gait speed (m/s) | 0.85 | (0.55–0.95) | 0.91 | (0.74–1.25) | 0.08 |